Multiple ALK receptor tyrosine kinase (ALK) inhibitors have upended the evidence-based management of advanced NSCLC over the last half decade.1 Crizotinib was the first ALK inhibitor to reach regulatory approval in the first-line management of ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC, and the next-generation ALK inhibitors ceritinib, alectinib, and brigatinib are highly active after intracranial or systemic progression during crizotinib therapy.1 More recently, alectinib improved outcomes in the treatment-naive setting in comparison with crizotinib, and ceritinib was shown to be superior to cytotoxic therapies in the same setting.1 The management of ALK-rearranged tumors that become biologically resistant to next-generation ALK inhibitors continues to be undefined, but knowledge of the mechanism of resistance may allow for sequencing of approved or in-development ALK inhibitors.2, 3, 4, 5 Here, we present what, to the best of our knowledge, is the first reported case..... READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2018.06.020
Authors: Kartik Sehgal, Mary Linton B. Peters, Paul A. VanderLaan, Deepa Rangachari, Susumu S. Kobayashi, Daniel B. Costa
